Great Point Partners’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Great Point Partners’s Portfolio PNT Stock Details PNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-2,909,960	Closed	-$19.4M	–	52
2023 Q3	$19.4M	Sell	2,909,960 -90,040	-3%	-$748K	3.54%	11
2023 Q2	$27.2M	Sell	3,000,000 -383,029	-11%	-$3.38M	5.32%	6
2023 Q1	$24.6M	Buy	3,383,029 +841,250	+33%	+$6.24M	4.83%	7
2022 Q4	$18.5M	Sell	2,541,779 -1,019,205	-29%	-$7.56M	3.63%	8
2022 Q3	$27.5M	Buy	3,560,984 +1,140,483	+47%	+$9.68M	6.63%	3
2022 Q2	$16.5M	Buy	2,420,501 +360,501	+18%	+$2.76M	3.95%	9
2022 Q1	$16.4M	Buy	2,060,000 +1,869,480	+981%	+$11.9M	3.97%	13
2021 Q4	$1.07M	Buy	+190,520	New	+$1.43M	0.24%	36

Other funds holding PNT

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Great Point Partners's PNT Position: Q4 2023 in Review

Great Point Partners sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q4 2023, closing a stake of 2,909,960 shares — an estimated $19.4M sold.

Great Point Partners first reported a position in PNT in Q4 2021 and held it in 8 quarters. The position peaked at $27.5M in Q3 2022. 1 fund tracked by Wall St. Rank holds PNT as of Q4 2023.

Great Point Partners reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Great Point Partners sold 2,909,960 POINT Biopharma Global Inc. Common Stock shares in Q4 2023, an estimated $19.4M.
Great Point Partners first reported a position in POINT Biopharma Global Inc. Common Stock in Q4 2021 and held it in 8 quarters.
Great Point Partners's POINT Biopharma Global Inc. Common Stock position peaked at $27.5M in Q3 2022.
1 fund tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q4 2023.

Based on Great Point Partners's 13F filing for Q4 2023, filed 14 Feb 2024.